<DOC>
	<DOCNO>NCT02813408</DOCNO>
	<brief_summary>The purpose observational study metastatic castration-resistant prostate cancer ( mCRPC ) participant explore whether difference participant treat abiraterone acetate enzalutamide health-related quality life ( HRQoL ) , Fatigue , Pain , Cognitive function medical resource use ( MRU ) .</brief_summary>
	<brief_title>A Study Investigate Impact Abiraterone Acetate Enzalutamide Health-related Quality Life , Participant-Reported Outcomes , Medical Resource Use Metastatic Castration-resistant Prostate Cancer Participants</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Male 18 year age old Participant histologically cytologically confirm diagnosis adenocarcinoma prostate Participant document metastatic prostate cancer Participant document castration resistance progression prostate cancer androgen deprivation therapy ( ADT ) Participant initiate either abiraterone acetate enzalutamide treatment metastatic castrationresistant prostate cancer ( mCRPC ) asymptomatic mildly symptomatic ( per physician 's evaluation ) failure ADT time treatment initiation Participants sign participation agreement Informed consent form ( ICF ) per local regulation The treatment decision ( abiraterone acetate enzalutamide ) treat physician must take enrollment study Baseline patientreported outcomes ( PROs ) must capture first administration abiraterone acetate enzalutamide . Patient receive chemotherapy/cytotoxic agent treat mCRPC abiraterone acetate enzalutamide initiation ; ; treat metastatic hormonesensitive prostate cancer ( mHSPC ) &lt; 12 month prior abiraterone acetate enzalutamide initiation . Participant capable complete patient survey Participant receive currently receive abiraterone acetate enzalutamide Patient receive investigational treatment prostate cancer kind time initiation abiraterone acetate enzalutamide Participant currently include observational study abiraterone acetate sponsor Janssen</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>